Highlights Newsletter 4
This newsletter presents you the following key sessions:
3. Nivolumab plus cabozantinib as new first-line treatment option for advanced renal cell carcinoma
This newsletter presents you the following key sessions:
3. Nivolumab plus cabozantinib as new first-line treatment option for advanced renal cell carcinoma
Medical writer
Medical writer